Physician profile
Wayne S Weidenbaum
NPI 1619945367
$1,608.22
in general payments reported to CMS, 2019-2025
23 companies · $671 in 2025
The $671 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $123 · 2021: $59.61 · 2022: $32.60 · 2023: $286 · 2024: $142 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $431.91 | 2019-2024 | Senza |
| Abbott Laboratories | $170.03 | 2019-2025 | Eterna, Proclaim |
| Globus Medical, INC. | $158.61 | 2025 | Senza |
| Si-Bone, INC. | $154.19 | 2025 | |
| Boston Scientific Corporation | $108.39 | 2019-2025 | Intracept |
| Relievant Medsystems, INC. | $102.03 | 2023 | Intracept |
| Abbvie INC. | $54.84 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $54.60 | 2025 | |
| Nalu Medical, INC. | $52.32 | 2021-2025 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $39.26 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $35.50 | 2019-2023 | Xtampza |
| Medtronic, INC. | $34.13 | 2025 | Inceptiv |
| Spr Therapeutics, INC | $32.08 | 2025 | Sprint Pns System |
| Biotronik Nro, INC. | $28.03 | 2025 | Prospera |
| Curonix LLC | $24.30 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $22.57 | 2023 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.85 | 2023 | Relistor |
| Vertiflex, INC. | $15.09 | 2019 | |
| Biodelivery Sciences International, INC. | $14.66 | 2019 | |
| Saluda Medical Americas, INC. | $14.65 | 2025 | Evoke |
| Allergan, INC. | $14.53 | 2019 | |
| Sentynl Therapeutics, INC. | $14.21 | 2019 | |
| Pfizer INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Weidenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.